Delay for Akcea's volanesorsen

Akcea Therapeutics Inc. (NASDAQ:AKCA) said it received a complete response letter for Waylivra volanesorsen to treat familial chylomicronemia syndrome (FCS), going against an FDA

Read the full 245 word article

User Sign In